Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 73

Results For "S-1"

939 News Found

Corbevax receives EUA for 12-18 age group
News | February 21, 2022

Corbevax receives EUA for 12-18 age group

It is India’s 1st indigenously developed Receptor Binding Domain Protein sub-unit vaccine against Covid-19


Sputnik Light gets a boost as China changes rules on boosters
News | February 21, 2022

Sputnik Light gets a boost as China changes rules on boosters

Sputnik Light can become a major booster for those vaccinated with inactivated Chinese Covid-19 vaccines globally after China has officially recommended mix & match approach with adenoviral vector-based vaccines as boosters


Gujarat unveils ambitious Biotech Policy 2022-27
Policy | February 21, 2022

Gujarat unveils ambitious Biotech Policy 2022-27

According to the state government, it will also provide support to special projects such as preclinical testing, genome sequencing in the private sector, private sector BSL-3 lab-vaccine development and manufacturing and testing and certification laboratories


SEBI approves IPO plans of PharmEasy and Wellness Forever Medicare
News | February 21, 2022

SEBI approves IPO plans of PharmEasy and Wellness Forever Medicare

The companies plan to use the proceeds to retire debt and expand operations


USFDA lifts clinical hold on submission of Covaxin
News | February 20, 2022

USFDA lifts clinical hold on submission of Covaxin

Covaxin is a whole-virion inactivated Covid-19 investigational vaccine candidate that uses the same vero cell manufacturing platform that has been used in the production of polio vaccines for decades


Fitch revises outlook on Jubilant Pharma to negative; affirms at 'BB'
News | February 19, 2022

Fitch revises outlook on Jubilant Pharma to negative; affirms at 'BB'

Fitch estimates JPL's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11% (FY22 estimate: 14%).


Natco Q3FY22 PAT up 27% to Rs 80 Cr
News | February 19, 2022

Natco Q3FY22 PAT up 27% to Rs 80 Cr

The company registered consolidated total revenue of Rs 590.70 crore for Q3FY22.


Quotient Sciences integrates drug substance into Translational Pharmaceutics Platform
Biotech | February 18, 2022

Quotient Sciences integrates drug substance into Translational Pharmaceutics Platform

The newly enhanced drug development platform will help empower innovators with the fastest development timelines


Moderna’s Covid-19 vaccine approved in Australia for children (6-11 years)
News | February 17, 2022

Moderna’s Covid-19 vaccine approved in Australia for children (6-11 years)

Moderna's vaccine has already received regulatory approval for adults and adolescents in Australia


Kato wins USFDA approval for studies in retinal disorder
Biotech | February 17, 2022

Kato wins USFDA approval for studies in retinal disorder

Resolv ER may remedy leading causes of blindness in adults